CLDI · Calidi Biotherapeutics, Inc.
$0.77
0.00 (-0.26%)
At close · Oct 21
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 13, 2026
Substantial doubt about the company's ability to continue as a going concern.
“The Company estimates that based on the Company's liquidity resources, there is substantial doubt about the Company's ability to continue as a going concern within 12 months from the date of issuance of these unaudited condensed consolidated financial statements.”View the 10-Q filed Aug 13, 2026
Market Cap
$1.98M
Shares
2.58M
Volume · Oct 21
63.67K
Avg daily vol (58 sessions)
150.32K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.77
Open$0.76
Day$0.73–0.79
52W close$0.77–26.56
Avg vol 30d165K
Short int233K · 9.0% float · 1.0d
Short vol31%
Last earningsSep 11, 2024
DataNov 2021–Oct 2026
Filing10-Q · Aug 13
Up next
filed Aug 13, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$17.40M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
-51,395.6%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$3.69M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+686.7%
Year over year · more shares
Price change (1Y)
—
Trailing year
Short interest
9.0%
Latest settlement · 1.0 days to cover
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Strong Sell
Momentum
Very Weak
Sentiment
Bearish
Fundamentals
Excellent
Quant / Vol
Very High
Market backdrop
VIX 16.7 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−85%
below
Price vs 50-day avg
−35%
below
RSI (14)
21
oversold
MACD trend
Negative
52-week position
0%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−30%
trailing
6-month return
−77%
trailing
YTD return
−96%
this year
Relative strength
−85%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $1 › 200d $5 — 200d above 50d
Institutional flow
Distributing
2 of 23 funds reported for Sep 30 · net -2.7K sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
9.03% of float · ▲ +2.4% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
23 holders — mid 3-yr range
Squeeze score
49
elevated · 0–100
Fundamentals
EPS growth
+83%
Y/Y
Balance sheet
$5.2M
net cash
Quant / Vol
risk profile
Volatility
93%
annualized · 1-yr
Max drawdown
−97%
past year
ATR
10.2%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−85%
Bearish
Price vs 50-day avg
−35%
Bearish
RSI (14)
21
Neutral
MACD trend
Negative
Bearish
52-week position
0%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $1 › 200d $5 — 200d above 50d
Institutional flow
Distributing
2 of 23 funds reported for Sep 30 · net -2.7K sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
9.03% of float · ▲ +2.4% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
23 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $1
Now $1 · 0%
Range high $27
vs 200-day avg -85%
vs 50-day avg -35%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CLDI
this stock
Calidi Biotherapeutics, Inc.
|
$1.98M | — | — | — | 9.0% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$131.39B | +15.7% | +46.2% | 30.2 | 1.8% |
|
MRNA
Moderna, Inc.
|
$96.65B | +733.5% | +4.3% | — | 7.7% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$83.13B | +4.4% | +20.8% | 20.0 | 2.1% |
|
CSLLY
Csl Ltd
|
$66.22B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CLDI | -12.1% | -29.5% | -77.0% | -28.2% | -95.9% |
| SPY | +0.5% | +0.7% | +7.6% | +1.4% | +13.4% |
| vs SPY | -12.6% | -30.2% | -84.6% | -29.6% | -109.3% |